ICML 2019 | Frontline ibrutinib-FCR for younger CLL patients: Phase II results

Matthew Davids

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the single-arm, multi-center, Phase II trial (NCT02251548) of ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFCR) as an initial treatment for younger patients with chronic lymphocytic leukemia (CLL). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video